Search Results - "HEIMANN, Pierre"
-
1
Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy
Published in Journal of translational medicine (05-09-2019)“…Treatment with anti-PD1 monoclonal antibodies improves the survival of metastatic melanoma patients but only a subgroup of patients benefits from durable…”
Get full text
Journal Article -
2
Eosinophilia Associated With CD3 - CD4 + T Cells: Characterization and Outcome of a Single-Center Cohort of 26 Patients
Published in Frontiers in immunology (11-08-2020)“…Lymphocytic variant hypereosinophilic syndrome is characterized by marked over-production of eosinophilopoietic factor(s) by dysregulated T cells leading to…”
Get full text
Journal Article -
3
Clinical Validation of Targeted Next Generation Sequencing for Colon and Lung Cancers
Published in PloS one (14-09-2015)“…Recently, Next Generation Sequencing (NGS) has begun to supplant other technologies for gene mutation testing that is now required for targeted therapies…”
Get full text
Journal Article -
4
microRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification
Published in Blood (21-05-2009)“…Aberrant expression of microRNAs has been recently associated with chronic lymphocytic leukemia (CLL) outcome. Although disease evolution can be predicted by…”
Get full text
Journal Article -
5
Rapid Progression of Angioimmunoblastic T Cell Lymphoma Following BNT162b2 mRNA Vaccine Booster Shot: A Case Report
Published in Frontiers in medicine (25-11-2021)“…Since nucleoside-modified mRNA vaccines strongly activate T follicular helper cells, it is important to explore the possible impact of approved SARS-CoV-2 mRNA…”
Get full text
Journal Article -
6
Human fetal neuroblast and neuroblastoma transcriptome analysis confirms neuroblast origin and highlights neuroblastoma candidate genes
Published in Genome Biology (01-01-2006)“…Neuroblastoma tumor cells are assumed to originate from primitive neuroblasts giving rise to the sympathetic nervous system. Because these precursor cells are…”
Get full text
Journal Article -
7
Transient leukemia in a newborn without Down syndrome: case report and review of the literature
Published in European journal of pediatrics (01-12-2014)“…Transient neonatal leukemia occurs almost exclusively in Down syndrome babies. We report here the unusual case of a newborn without Down syndrome who presented…”
Get full text
Journal Article Web Resource -
8
Indications of next-generation sequencing in non-Hodgkin's lymphoma
Published in Current opinion in oncology (01-09-2020)“…PURPOSE OF REVIEWIn this study, we will give an overview on the current and foreseeable indications of next-generation sequencing (NGS)-based technologies for…”
Get full text
Journal Article -
9
-
10
Alveolar soft-part sarcoma: Further evidence by FISH for the involvement of chromosome band 17q25
Published in Genes chromosomes & cancer (01-10-1998)“…A cytogenetic study of an alveolar soft‐part sarcoma, a rare tumor of probably myogenic origin, demonstrated a t(X;17)(p11;q25) as the sole chromosomal…”
Get full text
Journal Article -
11
Measurable residual disease assessment prior to allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndromes: a 20-year monocentric study
Published in Annals of hematology (01-11-2024)“…Patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) who undergo allogeneic hematopoietic stem-cell transplantation (alloHSCT) can…”
Get full text
Journal Article -
12
-
13
CD3−CD4+ Lymphocytic Variant Hypereosinophilic Syndrome: Diagnostic Tools Revisited
Published in The journal of allergy and clinical immunology in practice (Cambridge, MA) (01-06-2021)“…Identification of patients with lymphocytic variant hypereosinophilic syndrome (L-HES) is challenging, and has important prognostic and therapeutic…”
Get full text
Journal Article -
14
One-Step Duplex Droplet Digital PCR for WT1 Overexpression
Published in The Journal of molecular diagnostics : JMD (01-08-2020)“…With the improvement of treatment methods in acute hematology malignancies, the development of sensitive tools for minimal residual disease assessment has…”
Get full text
Journal Article -
15
Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy
Published in Melanoma research (01-02-2018)“…Anti-programmed death 1 (PD-1) monoclonal antibodies improve the survival of metastatic melanoma patients. Predictive or monitoring biomarkers for response to…”
Get full text
Journal Article -
16
Hyperdiploidy with 58-66 chromosomes in childhood B-acute lymphoblastic leukemia is highly curable: 58951 CLG-EORTC results
Published in Blood (28-03-2013)“…The aim of our study was to analyze the factors contributing to heterogeneity of prognosis in patients with hyperdiploidy>50 chromosomes (HD>50), a group of…”
Get full text
Journal Article -
17
Abstract 2293: Is a single driver gene mutation sufficient for monitoring early response in advanced colorectal cancer
Published in Cancer research (Chicago, Ill.) (01-07-2019)“…Purpose: Circulating tumor DNA (ctDNA) monitoring based on an individual mutation profile during therapy is under intense investigation in modern oncology. We…”
Get full text
Journal Article -
18
Case Report of an Unusual Tumor in an Adult With a TP53 Germline Mutation
Published in Clinical lymphoma, myeloma and leukemia (01-08-2021)Get full text
Journal Article -
19
Abstract LB-221: Circulating tumor DNA detects early response to regorafenib in advanced colorectal cancer
Published in Cancer research (Chicago, Ill.) (01-07-2018)“…Purpose: To demonstrate that an early increase in ctDNA plasmatic levels after 14 days may identify patients (pts) with advanced chemorefractory colorectal…”
Get full text
Journal Article -
20
Identification of chronic myeloid leukemia patients treated with imatinib who are potentially eligible for treatment discontinuation by assessing real-life molecular responses on the international scale in a EUTOS-certified lab
Published in Leukemia research (01-04-2018)“…•Real-life molecular responses on international scale in EUTOS-certified laboratory.•53.4% of patients were in deep molecular responses ≥MR4.5 at last…”
Get full text
Journal Article